EYEMATE-SC Biosensor monitors glaucoma via digitization.
FREMONT, CA: Implandata Ophthalmic Products’ EYEMATE-SC biosensor receives CE Mark certification. Implandata is a digital health company based in Germany and San Diego, California. EYEMATE-SC sensor is used in conjunction with the ground-breaking EYEMATE system to enable remote glaucoma monitoring and management via digital technology. The EYEMATE-SC is an enhanced version of the EYEMATE.
The trademarked EYEMATE system is the world’s only clinically validated remote glaucoma monitoring system. This device enables patients to self-monitor their intraocular pressure and then automatically transmits the data to their eye doctor or cloud-based storage in real-time. This information allows eye doctors to obtain detailed information about the effectiveness of therapy and adjust treatment accordingly, rather than making therapeutic adjustments based on a single IOP measurement obtained during an office visit.
Max G. Ostermeier, CEO and Founder of Implandata, states: “Obtaining CE mark for our less invasive EYEMATE-SC sensor as part of our validated EYEMATE system is another important step forward for the company to transform glaucoma care. This new version is expanding the addressable glaucoma patient segment and is more readily and safely implanted than the earlier device. With CE mark, we will start to launch the product with various eye centers across Europe.”
Robert N. Weinreb, MD, Chair and Distinguished Professor of Ophthalmology at the University of California, San Diego and Implandata Medical Advisor comments: “Millions of individuals worldwide are at risk of permanent loss of their vision due to glaucoma. With the EYEMATE, intraocular pressure now can be monitored more closely to personalize treatment and avoid further vision loss.”
Kaweh Mansouri, MD, MPH, Consultant ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland, Adjoint Professor at the Department of Ophthalmology, University of Colorado, Denver, and one of the lead investigators in the clinical study validating the EYEMATE-SC biosensor concludes: “With CE Mark of the EYEMATE-SC biosensor we can now start to introduce the EYEMATE system into our clinical routine, which we have eagerly waited for. Our team has been very pleased with the safety and the performance of the product in our clinical study and is very happy by how well the product is accepted by our patients. EYEMATE will help us to make more informed therapeutic decisions faster. This technology empowers patients, resulting in improved adherence with therapy and less worries about undetected IOP peaks and glaucoma progression.”